Select company
- Ticker/CompanyMarket Cap.
No results found
Select metric
Pick a metric...
$ -79.44MEarnings Before Interest Taxes & Depreciation Amortization (EBITDA)
VS
Market
Sector
Industry
History
$ 18.81Close
$ 7.38 - $ 61.57 52-Week Range
Ticker Information
Ticker
TNXPCompany Name
TONIX PHARMACEUTICALS HOLDING CORPSector
HealthcareIndustry
BiotechnologyExchange
NASDAQTONIX PHARMACEUTICALS HOLDING CORP - Earnings Before Interest Taxes & Depreciation Amortization (EBITDA) Chart Analysis (TTM)
From
Zoom
1Y
3Y
5Y
10Y
TNXP - EBITDA Historical data
| Date | Depreciation, Amortization & Accretion | Earning Before Interest & Taxes (EBIT) | Earnings Before Interest Taxes & Depreciation Amortization (EBITDA) |
|---|---|---|---|
| 6/30/2025 | $ 1.98M | $ -81.42M | $ -79.44M |
| 3/31/2025 | $ 2.7M | $ -131.93M | $ -129.22M |
| 12/31/2024 | $ 3.42M | $ -130.04M | $ -126.61M |
| 9/30/2024 | $ 4.19M | $ -135.25M | $ -131.06M |
| 6/30/2024 | $ 4.89M | $ -149.01M | $ -144.12M |
| 3/31/2024 | $ 4.61M | $ -98.59M | $ -93.98M |
| 12/31/2023 | $ 4.29M | $ -116.66M | $ -112.37M |
| 9/30/2023 | $ 3.87M | $ -121.02M | $ -117.15M |
| 6/30/2023 | $ 2.9M | $ -122.02M | $ -119.12M |
| 3/31/2023 | $ 2.08M | $ -116.81M | $ -114.72M |
Key Performance Insights, Last 5 Years
- TONIX PHARMACEUTICALS HOLDING CORP's latest trailing twelve months (TTM) EBITDA stands at $ -42.12M.
- Over the past 5 years, TONIX PHARMACEUTICALS HOLDING CORP's average EBITDA has been $ -99.07M.
- The median EBITDA for TONIX PHARMACEUTICALS HOLDING CORP during this period was $ -102.8M
- TONIX PHARMACEUTICALS HOLDING CORP reached its highest EBITDA over the past 5 years at $ -42.12M.
- The lowest EBITDA recorded by TONIX PHARMACEUTICALS HOLDING CORP in the same timeframe $ -144.12M
TONIX PHARMACEUTICALS HOLDING CORP's EBITDA vs. competitors
We picked the following companies as peers based on multiple factors, including sector, industry, market capitalization and revenue
EBITDA Benchmarks
Similar metrics to EBITDA:
- Depreciation, Amortization & Accretion - [Cash Flow Statement] A component of operating cash flow [NCFO] representing the aggregate net amount of depreciation, amortization, and accretion recognized during an accounting period. As a non-cash item, the net amount is added back to net income when calculating cash provided by operations.
- Enterprise Value over EBITDA - [Calculation] Measures a company’s Enterprise Value [EV] in relation to its earnings before interest, taxes, depreciation, and amortization [EBITDA].
- EBITDA per Share - [Calculation] The amount of earnings before interest, taxes, depreciation, and amortization attributed to each share, calculated as [EBITDA] divided by the weighted average number of shares [SharesWA] after adjusting for [ShareFactor].
- Earning Before Interest & Taxes (EBIT) - [Income Statement] Earnings before interest and taxes measures a company's net income [NetInc] prior to the deduction of interest [IntExp] and tax expenses [TaxExp].
- EBITDA Margin - [Calculation] A company’s [EBITDA] as a percentage of [Revenue]. Measures how much earnings a company produces for each dollar of revenue generated before interest, taxes, depreciation and amortization.
Definition of Earnings Before Interest Taxes & Depreciation Amortization (EBITDA)
[Calculation] EBITDA is a non-GAAP accounting metric that lets investors asses profitability net of expenses dependent on financing decision, tax strategy and depreciation schedules. It is calculated by adding depreciation and amortisation expenses [DepAmor] back to [EBIT].EBIT + DepAmor
(=) EBITDA EBITDA for TONIX PHARMACEUTICALS HOLDING CORP is calculated as follows: EBIT [ $ -42.15M ] + DepAmor [ $ 25K ]
(=) EBITDA [ $ -42.12M ] TNXP - Earnings Before Interest Taxes & Depreciation Amortization (EBITDA), Last 5 years
$ -144.12M
Minimum
Jun 30, 2024
$ -42.12M
Maximum
Sep 30, 2020
$ -99.07M
Average
$ -102.8M
Median
EBITDA Benchmark AnalysisMarket
The chart above depicts the distribution of EBITDA for companies in the Total Stock Market. The average EBITDA of the companies is $ 58.79M with a standard deviation of $ 166.94M.
The following table provides additional summary stats:
EBITDA in the Market:
| filtered constituents | 3.25K |
|---|---|
| min | $ -493.3M |
| max | $ 590.6M |
| average | $ 58.79M |
| median | $ 8.83M |
| std | $ 166.94M |